Sphingosine kinase 1 a new tumor target for enhancing the potency of immune checkpoint inhibitors inhibitor for the treatment of cancer

The present invention relates to methods for enhancing the potency of the immune checkpoint inhibitors. In particular, the present invention relates to a method for enhancing the potency of an immune checkpoint inhibitor administered to a subject as part of a treatment regimen, the method comprising administering a pharmaceutically effective amount of a SK1 inhibitor to a subject in combination with the immune checkpoint inhibitor.

Keywords: SK1 inhibitor, melanoma, combination, immune checkpoint inhibitor

Patent Application number: European Procedure (Patents) (EPA) - 28 Janv. 2016 - 16 305 084.2

Inventors:

COLACIOS CélineANDRIEU-ABADIE NathalieSEGUI BrunoIMBERT CarolineMEYER Nicolas

Publications:

Downregulation of sphingosine kinase-1 induces protective tumor immunity by promoting M1 macrophage response in melanoma. Mrad M. et al. Oncotarget 2016 Nov 1;7(44):71873-71886Resistance of Melanoma to Immune Checkpoint Inhibitors Is Overcome by Targeting the Sphingosine kinase-1 Imbert C et al. Nat Commun. 2020 Jan 23;11(1):437

Reference:

BIO15451-T1

Anne COCHI
Business Development Manager

Phone

E-mail

Patent filling date: 28-01-2016

Rare disease: No

Second indication: No

Sphingosine kinase 1 a new tumor target for enhancing the potency of immune checkpoint inhibitors inhibitor for the treatment of cancer

You might also be interested in